Tianjin Chase Sun Pharmaceutical: Shareholder Tianjin Datong Investment releases pledge of 10 million shares
NBD AI Bulletin - Tianjin Chase Sun Pharmaceutical Co., Ltd. ("the Company", SZ 300026, close price: 4.4 yuan) announced on January 19 that on January 15, 2021, the Company's shareholder Tianjin Datong Investment released the pledge of 10 million shares that were originally pledged to Tianjin Trust Co., Ltd. and account for about 4.76% of its holdings. As at the date of this notice, the total number of pledged shares of Tianjin Datong Investment was about 203 million shares, accounting for about 96.71% of its holdings.
The 2019 annual report shows that the main business of Tianjin Chase Sun Pharmaceutical Co., Ltd. is Chinese herbal formula granules and tablets, finished medicines, medical devices, accessories and APIs, other industries, accounting for 54.09%, 21.2%, 13.09%, 8.44%, 3.18% of revenue, respectively.
Tianjin Chase Sun Pharmaceutical Co., Ltd. is chaired by Yao Xiaoqing, male, 56 years old, Chinese national, no permanent residence abroad, Ph.D., practising physician. Tianjin Chase Sun Pharmaceutical Co., Ltd.'s general manager is Zheng Dan, female, 57 years old, Chinese national, no permanent residence abroad, with a master's degree.
Tips on "Stock Trends":
1. The number of shares held by northbound investors in the Company increased by 3.4385 million in the past 30 days, representing 0.13% of the Company's circulating shares.
2. There was no institutional research on the Company in the past 30 days.
(By Lan Suying)
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.